Rashmin Dhanani
Primary Care · Hoover, ALNPI 1992349690
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 269 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 19.0% — the pattern of someone who eats at a lot of different presentations.
Across 269 payments — averaging $18.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$964
- UCB, Inc.$704
- AbbVie$683
- AstraZeneca$564
- Novartis$414
- Johnson & Johnson$310
- plus $1K from 14 others
What the payments were for
- Food & beverage$5,069100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 62 | $964 |
| UCB, Inc. | 45 | $704 |
| AbbVie | 35 | $683 |
| AstraZeneca(2 entities) | 28 | $564 |
| Novartis | 16 | $414 |
| Johnson & Johnson | 16 | $310 |
| ANI Pharmaceuticals, Inc. | 10 | $295 |
| Pfizer | 17 | $281 |
| GSK | 12 | $257 |
| Radius Health, Inc. | 6 | $118 |
| Sobi, Inc | 3 | $79 |
| Sandoz | 4 | $77 |
| Fresenius Kabi USA, LLC | 5 | $72 |
| Lilly USA, LLC | 2 | $55 |
| Boehringer Ingelheim | 2 | $49 |
| Aurinia Pharma U.S., Inc. | 2 | $43 |
| Atland Pharmaceuticals, LLC | 1 | $37 |
| Sanofi | 1 | $27 |
| Genentech USA, Inc. | 1 | $22 |
| Kyowa Kirin, Inc. | 1 | $17 |
How this compares
$5,069 in reported general payments places this provider in the 85th percentile of 159 primary care providers in Alabama.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 23 | $155,497 |
| Enbrel SureclickEtanercept | 16 | $118,534 |
| Orencia ClickjectAbatacept | 18 | $102,101 |
| Cimzia (2 Pack)Certolizumab Pegol | 11 | $67,283 |
| KevzaraSarilumab | 11 | $46,445 |
| OlumiantBaricitinib | 11 | $30,299 |
| Hydroxychloroquine Sulfate | 285 | $18,447 |
| Duloxetine Hcl | 214 | $8,314 |
| Leflunomide | 68 | $7,034 |
| MethotrexateMethotrexate Sodium | 177 | $6,970 |
| Colchicine | 39 | $4,397 |
| Pilocarpine Hcl | 50 | $4,054 |
| Diclofenac Sodium | 144 | $3,241 |
| Sulfasalazine | 57 | $1,368 |
| Prednisone | 208 | $1,270 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| UCB, Inc.Cimzia (2 Pack) | $704 | $67,28311 claims |
| SanofiKevzara | $27 | $46,44511 claims |
| Lilly USA, LLCOlumiant | $55 | $30,29911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 159 primary care providers in Alabama.
Other primary care in Hoover
- Amber NelsonHoover$9K
- Farzana GilaniHoover$2K
- Keith MatthewsOpelika$20K
- Troy HendersonFultondale$18K
- April TateDothan$16K
- Brandy McGrawMobile$14K
- Cleo ValdezHuntsville$14K
- Larissa RobinsonJasper$11K
- Jamie GhrigsbyMoulton$9K
- Josh WarrenBirmingham$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.